NeuroOne Medical shares jump 11.12% after-hours as Q4 2025 revenue estimates rise to $2.47M, despite expected $0.04 loss per share.

NeuroOne Medical Technologies Corp (NASDAQ:NMTC) surged 11.12% in after-hours trading following the announcement of its Q4 2025 earnings release scheduled for Dec 17, 2025. The stock’s rally aligns with improved revenue estimates, which rose to $2.47 million for Q4 2025 and $8.90 million for full-year 2025, reflecting stronger-than-previous projections. Despite expected losses of $0.04 per share for the quarter and $0.12 per share for the year, analysts highlighted positive momentum from the company’s prior earnings beat in Q3 2025 (40% better than expected) and a "Buy" consensus rating from brokerage firms. Price targets suggest significant upside potential, with an average target of $2.23 (326% from current levels) and GuruFocus estimating $2.57 in one year. The after-hours jump reflects investor optimism around the firm’s revenue growth trajectory and analyst confidence in its long-term recovery.